top of page
Latest News

News

Press Releases

2024

JULY 18

Vergent Bioscience Data Published in The Annals of Thoracic Surgery Demonstrate VGT-309 May Help Surgeons Visualize Tumor Tissue in the Lung During Surgery

2024

JANUARY 28

Vergent Bioscience Presents Phase 2 Data Showing VGT-309 Visualizes Tumors in the Lung During Surgery

2024

JANUARY 17

Vergent Bioscience to Present New Efficacy Results from Phase 2 Clinical Trial of VGT-309 at Annual Meeting of The Society of Thoracic Surgeons

2023

DECEMBER 13

Vergent Bioscience Initiates Phase 2, Multi-Center VISUALIZE Study Evaluating Efficacy of Tumor-targeted Fluorescent Imaging Agent VGT-309 in Lung Cancer Surgeries

2023

SEPTEMBER 11

Phase 2 Data Demonstrate Potential of Vergent Biosciences’ Tumor-Targeted Fluorescent Imaging Agent to Improve Success of Lung Cancer Surgeries

2023

AUGUST 16

Vergent Bioscience to Present Phase 2 Clinical Data for VGT-309 at IASLC 2023 World Conference on Lung Cancer

2022

NOVEMBER 29

Vergent Bioscience Awarded National Cancer Institute Phase 2 Grant to Advance Clinical Development of VGT-309 in Lung Cancer

2022

OCTOBER 4

Vergent Bioscience Secures $21.5 Million Series B Financing to Advance Clinical Development of Tumor-Targeted Fluorescent Imaging Agent VGT-309

Media Coverage

The Dye that Binds: Advances in Tumor Visualization Now Help Surgeons See Cancer in Real-Time

As surgical oncology moves toward increased adoption of minimally invasive techniques and procedures, the ability to locate and see tumors is vital. Once a surgeon loses the ability to visualize directly and use tactile sensation to identify and locate tumors, what can provide that needed layer of confidence?

bottom of page